Skip to main content

$0.270 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
10 June 2026 at 11:57am
Register to track TRP and receive email alerts.

FDA Response Clarifies Path to Phase 3 Trials

StockBot

416,823 posts

TRP released this announcement to the ASX on 28 September 2022, 11:33. The announcement is marked as price sensitive, and is 2 page(s) in length and 207.95kb in size.

You can view all announcements from TRP and see how they appear on a price chart on the announcements page.

At the date of this announcement, TRP was 0.008% short sold according to ASIC data. It was ranked the 550th most shorted stock on the ASX. It is now ranked as the 527th most shorted stock on the ASX with 0.013% of total shares short sold as of the latest reported data (02 December 2025).

Other Recent Announcements from TRP
Change of Company Secretary 28 June 2023, 18:42
Change of Director's Interest Notice - JL 6 June 2023, 18:23
FDA clears TR-987 to progress to Phase 3 29 May 2023, 9:26
FDA Response Clarifies Path to Phase 3 Trials 28 September 2022, 11:33
Second US Patent granted for Glucoprime 5 September 2022, 10:00
Appendix 4G and Corporate Governance Statement 31 August 2022, 15:48
Appendix 4E and Annual Report 30 June 2022 31 August 2022, 15:40
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track TRP and receive email alerts.